1995 Results

People

  1. Kris
    Kris
  2. Motzer
    Motzer
  3. Scher
    Scher
  4. Saltz
    Saltz
  5. Schwartz
    Schwartz
  6. Hudis
    Hudis
  7. Kelsen
    Kelsen
  8. Rosen
    Rosen
  9. Marks
    Marks
  10. De Angelis
    De Angelis

Groups

  1. Department of Medicine (969)
  2. Solid Tumor Oncology Division (729)
  3. Surgery (289)
  4. GSK Faculty (287)
  5. Survivorship Research (260)
  6. Center for Hematologic Malignancies (230)
  7. Sloan Kettering Institute Faculty (227)
  8. Hematologic Malignancies, Division of (224)
  9. Genitourinary Oncology Service (203)
  10. Molecular Pharmacology and Chemistry Program Faculty (172)
  1. "antineoplastic agents"
Formats
  1. Journal Article (1901)
  2. Review (47)
  3. Conference Paper (23)
  4. Editorial (7)
  5. Research Letter (6)
  6. Guidelines (4)
  7. Book Section (3)
  8. Correspondence (2)
  9. Meeting Abstract (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (969)
  2. Solid Tumor Oncology Division (729)
  3. Surgery (289)
  4. GSK Faculty (287)
  5. Survivorship Research (260)
  6. Center for Hematologic Malignancies (230)

More Groups

People
  1. Mark Kris (77)
  2. Robert Motzer (70)
  3. Howard Scher (58)
  4. Gary Schwartz (52)
  5. Leonard Saltz (52)
  6. Ting-Chao Chou (50)

More People

Years
  1. 2025 (16)
  2. 2024 (65)
  3. 2023 (49)
  4. 2022 (49)
  5. 2021 (11)
  6. 2020 (4)

More Years

Publications
  1. Clinical Cancer Research (114)
  2. Journal of Clinical Oncology (111)
  3. Cancer (70)
  4. Seminars in Oncology (51)
  5. New England Journal of Medicine (43)
  6. Cancer Research (40)

More Publications

Publishers
  1. Elsevier Inc. (240)
  2. American Association for Cancer Research (187)
  3. Springer (175)
  4. American Society of Clinical Oncology (129)
  5. Wiley Blackwell (112)
  6. Nature Publishing Group (92)

More Publishers

Results (1995)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • NCCN Guidelines® Insights: Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 3.2022: Featured updates to the NCCN Guidelines
    Guidelines

    Wierda, W. G.; Brown, J.; Abramson, J. S.; Awan, F.; Bilgrami, S. F.; Bociek, G.; Brander, D.; Chanan-Khan, A. A.; Coutre, S. E.; Davis, R. S.; more...
    Journal of the National Comprehensive Cancer Network (2022)

    Fulltext@MSK | Save
  • Leukotrienes promote stem cell self-renewal and chemoresistance in acute myeloid leukemia
    Journal Article

    Stranahan, A. W.; Berezniuk, I.; Chakraborty, S.; Feller, F.; Khalaj, M.; Park, C. Y.
    Leukemia (2022)

    Fulltext@MSK | Save
  • FGFR2::TACC2 fusion as a novel KIT-independent mechanism of targeted therapy failure in a multidrug-resistant gastrointestinal stromal tumor
    Journal Article

    Dermawan, J. K.; Vanderbilt, C. M.; Chang, J. C.; Untch, B. R.; Singer, S.; Chi, P.; Tap, W. D.; Antonescu, C. R.
    Genes Chromosomes and Cancer (2022)

    Fulltext@MSK | Save
  • Bystander effect of antibody–drug conjugates: Fact or fiction?
    Review

    Giugliano, F.; Corti, C.; Tarantino, P.; Michelini, F.; Curigliano, G.
    Current Oncology Reports (2022)

    Fulltext@MSK | Save
  • Simplified graded infusion strategy for mitigation of oxaliplatin hypersensitivity
    Journal Article

    Alonso Martinez, S.; Segal, N. H.; Cercek, A.; Yaeger, R.; Stadler, Z.; Kemeny, N. E.; Nusrat, M.; Shahrokni, A.; Connell, L.; Saltz, L. B.
    Clinical Colorectal Cancer (2022)

    Fulltext@MSK | Save
  • Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: An open-label phase I/II trial
    Journal Article

    Boni, V.; Fidler, M. J.; Arkenau, H. T.; Spira, A.; Meric-Bernstam, F.; Uboha, N.; Sanborn, R. E.; Sweis, R. F.; LoRusso, P.; Nagasaka, M.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
    Journal Article

    Waguespack, S. G.; Drilon, A.; Lin, J. J.; Brose, M. S.; McDermott, R.; Almubarak, M.; Bauman, J.; Casanova, M.; Krishnamurthy, A.; Kummar, S.; more...
    European Journal of Endocrinology (2022)

    Fulltext@MSK | Save
  • NCCN Guidelines® Insights: Hematopoietic growth factors, version 1.2022: Featured updates to the NCCN Guidelines
    Guidelines

    Griffiths, E. A.; Roy, V.; Alwan, L.; Bachiashvili, K.; Baird, J.; Cool, R.; Dinner, S.; Geyer, M.; Glaspy, J.; Gojo, I.; more...
    Journal of the National Comprehensive Cancer Network (2022)

    Fulltext@MSK | Save
  • Reaching beyond maximum grade: Progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies
    Review

    Thanarajasingam, G.; Minasian, L. M.; Bhatnagar, V.; Cavalli, F.; De Claro, R. A.; Dueck, A. C.; El-Galaly, T. C.; Everest, N.; Geissler, J.; Gisselbrecht, C.; more...
    The Lancet Haematology (2022)

    Fulltext@MSK | Save
  • A preclinical platform for assessing antitumor effects and systemic toxicities of cancer drug targets
    Journal Article

    Li, X.; Huang, C. H.; Sánchez-Rivera, F. J.; Kennedy, M. C.; Tschaharganeh, D. F.; Morris, J. P. 4th; Montinaro, A.; O'Rourke, K. P.; Banito, A.; Wilkinson, J. E.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2022)

    Fulltext@MSK | Save